EcoDrugPlus

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1c-Like

Ensembl ID : ENSAPOG00000009579
Gene Symbol: LOC110952819
3 Cross references
215 Possible Orthologues:

Voltage-Dependent L-Type Calcium Channel Subunit Alpha-1d-Like

Ensembl ID : ENSAPOG00000004538
Gene Symbol: LOC110955249
3 Cross references
212 Possible Orthologues:

Voltage-Dependent P/q-Type Calcium Channel Subunit Alpha-1a-Like

Ensembl ID : ENSAPOG00000017246
Gene Symbol: LOC110962524
3 Cross references
196 Possible Orthologues:

Voltage-Dependent T-Type Calcium Channel Subunit Alpha-1i-Like

Ensembl ID : ENSAPOG00000006599
Gene Symbol: LOC110951180
2 Cross references
206 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSAPOG00000015694
Gene Symbol: LOC110956796
2 Cross references
194 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit-Like

Ensembl ID : ENSAPOG00000001352
Gene Symbol: LOC110958789
2 Cross references
193 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSAPOG00000024480
Gene Symbol: LOC110956515
3 Cross references
168 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-4 Subunit-Like

Ensembl ID : ENSAPOG00000006662
Gene Symbol: LOC110963486
3 Cross references
192 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-7 Subunit-Like

Ensembl ID : ENSAPOG00000024484
Gene Symbol: LOC110956514
4 Cross references
188 Possible Orthologues:

Voltage-Dependent Calcium Channel Subunit Alpha-2/delta-1-Like

Ensembl ID : ENSAPOG00000000467
Gene Symbol: LOC110948569
3 Cross references
227 Possible Orthologues:

Ensembl ID : ENSAPOG00000023289
Gene Symbol: -
Cross references: -
221 Possible Orthologues:

Ensembl ID : ENSAPOG00000011715
Gene Symbol: -
Cross references: -
137 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).